Has Rituximab been included in medical insurance?

Rituximabhas been included in the scope of medical insurance. It is a Class B drug and can be reimbursed according to the prescribed proportion. Rituximab is a genetically engineered chimeric mouse/human monoclonal antibody that targets the CD20 antigen on the surface of normal and malignant B lymphocytes.

Rituximab is indicated as monotherapy for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20positiveB cell non-Hodgkin lymphoma (NHL). In addition, it is indicated for the treatment of adult patients with previously untreated follicular BB cell non-Hodgkin lymphoma in combination with first-line chemotherapy and as single-agent maintenance therapy in patients who have achieved a complete or partial response to a rituximab product in combination with chemotherapy. In addition, rituximab is indicated for the treatment of non-progressive (including stable disease), low-grade, and chronic disease after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. pan>CD20PositiveB cellsNHL Single drug therapy and previously untreated diffuse largeB cells, CD20positiveNHLcombination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.

Rituximab is indicated in combination with fludarabine and cyclophosphamide (FC) for the treatment of adult patients with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL). Rituximab in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have not responded to treatment with one or more TNF antagonists. In addition, rituximab is indicated in combination with corticosteroids for the treatment of adult and pediatric patients 2 years and older with granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) and microscopic polyangiitis (MPA).

Rituximab (intravenous rituximab injection) is suitable for patients 6 months and older with previously untreated advanced CD20 positive diffuse large B cell lymphoma (DLBCL), Burkitt lymphoma (DLBCL) combination therapy with chemotherapy in pediatric patients with pan>BL), Burkitt-like lymphoma (BLL), or matureBcell acute leukemia (B-AL); and treatment of adult patients with moderate to severe pemphigus vulgaris. 12Rituximab biosimilar products (rituximab-arrx, rituximab span>-abb, rituximab-pvvr) do not include these indications for rituximab in their labels. 13,14,15The combination product rituximabHYCELA (rituximab and hyaluronidase human injection for subcutaneous injection) is not suitable for the treatment of non-malignant diseases. IndiaReliancePharmaceutical retail price50ml:500mg1More than a thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.